Evaluation of Hepatitis B screening and reactivation in patients receiving rituximab containing chemotherapy: A single-centre study

被引:5
作者
Bozkurt, Ilkay [1 ]
Cerik, Hatun Ozturk [1 ]
Kir, Seher [2 ]
Ustaoglu, Muge [3 ]
Turgut, Mehmet [4 ]
Esen, Saban [1 ]
机构
[1] Ondokuz Mayis Univ, Sch Med, Dept Infect Dis, Samsun, Turkey
[2] Ondokuz Mayis Univ, Sch Med, Dept Internal Med, Samsun, Turkey
[3] Ondokuz Mayis Univ, Sch Med, Dept Gastroenterol, Samsun, Turkey
[4] Ondokuz Mayis Univ, Sch Med, Dept Hematol, Samsun, Turkey
关键词
HEMATOLOGICAL MALIGNANCIES; VIRUS REACTIVATION; MANAGEMENT; LYMPHOMA; THERAPY; ANTIBODY; RISK;
D O I
10.1111/ijcp.14685
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Hepatitis B virus (HBV) infection is a worldwide distributing viral disease. Hepatitis caused by HBV reactivation may progress to chronic illness and associated with increased risk of hepatic failure and hepatocellular cancer. Rituximab (RTX) is an immunosuppressive agent, is particularly used in the treatment of non-Hodgkin's Lymphoma. Patients have significant risk for HBV reactivation following chemotherapy with a RTX-containing regimen. This study aimed to determine the HBV screening manner and reactivation rates in patients with haematological neoplasm following chemotherapy including Rituximab. Methods This is a single-centered retrospective cohort study. A total of 331 adults with haematological disorders who received chemotherapy regimen including RTX between years of 2006 and 2016 were enrolled. Patients who experienced reactivation were evaluated. Results Only 130 of 331 patients were screened appropriately for HBV infection for 10-year period. We found 18 patients were Hepatitis B surface antigen (HBsAg) (+) and 16 (88.8%) of them received antiviral prophylaxis. Among screened patients, 27 were HBsAg (-)/AntiHBc (+) and only 10 (37%) of them received HBV prophylaxis. In total, nine patients experienced reactivation, six were from screened and three were from unscreened group. Conclusion Incomplete screening and inappropriate prophylaxis may result in HBV reactivation in patients under RTX-based chemotherapy and related complications such as death.
引用
收藏
页数:6
相关论文
共 20 条
  • [1] Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report
    Aygen, Bilgehan
    Demir, Ahmet Muzaffer
    Gumus, Mahmut
    Karabay, Oguz
    Kaymakoglu, Sabahattin
    Koksal, Aydin Seref
    Koksal, Iftihar
    Ormeci, Necati
    Tabak, Fehmi
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2018, 29 (03) : 259 - 269
  • [2] Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology
    Bengsch, Bertram
    Chang, Kyong-Mi
    [J]. CLINICS IN LIVER DISEASE, 2016, 20 (04) : 629 - +
  • [3] Management of patients with hepatitis B in special populations
    Cholongitas, Evangelos
    Tziomalos, Konstantinos
    Pipili, Chrysoula
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (06) : 1738 - 1748
  • [4] Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis
    Dong, Hua-Jie
    Ni, Ling-Na
    Sheng, Gui-Feng
    Song, Hong-Lei
    Xu, Jian-Zhong
    Ling, Yang
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2013, 57 (03) : 209 - 214
  • [5] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
    Lampertico P.
    Agarwal K.
    Berg T.
    Buti M.
    Janssen H.L.A.
    Papatheodoridis G.
    Zoulim F.
    Tacke F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
  • [6] Improvements in Hepatitis B Virus Screening Before Rituximab Therapy: A Community-Based, Safety-Net Hospital Experience
    Junus, Kevin
    Aguilar, Maria
    Patel, Priya
    Irwin, David
    Yee, Stephen
    Liu, Benny
    Bhuket, Taft
    Wong, Robert J.
    [J]. CANCER, 2017, 123 (04) : 650 - 656
  • [7] The Prevalence of "Anti-HBc Alone" and HBV DNA Detection Among Anti-HBc Alone in Korea
    Kang, So-Young
    Kim, Myeong-Hee
    Lee, Woo-In
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (09) : 1508 - 1514
  • [8] Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy
    Law, Man Fai
    Ho, Rita
    Cheung, Carmen K. M.
    Tam, Lydia H. P.
    Ma, Karen
    So, Kent C. Y.
    Ip, Bonaventure
    So, Jacqueline
    Lai, Jennifer
    Ng, Joyce
    Tam, Tommy H. C.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (28) : 6484 - 6500
  • [9] Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma
    Liu, Wei Ping
    Wang, Xiao Pei
    Zheng, Wen
    Ping, Ling Yan
    Zhang, Chen
    Wang, Gui Qiang
    Song, Yu Qin
    Zhu, Jun
    [J]. LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1355 - 1362
  • [10] Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
    Loomba, Rohit
    Liang, T. Jake
    [J]. GASTROENTEROLOGY, 2017, 152 (06) : 1297 - 1309